Yu D - Search Results

1

Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways.

Zhang S, Huang WC, Li P, Guo H, Poh SB, Brady SW, Xiong Y, Tseng LM, Li SH, Ding Z, Sahin AA, Esteva FJ, Hortobagyi GN, Yu D. Zhang S, et al. Among authors: yu d. Nat Med. 2011 Apr;17(4):461-9. doi: 10.1038/nm.2309. Epub 2011 Mar 13. Nat Med. 2011. PMID: 21399647 Free PMC article.

2

Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms.

Yu D, Liu B, Tan M, Li J, Wang SS, Hung MC. Yu D, et al. Oncogene. 1996 Sep 19;13(6):1359-65. Oncogene. 1996. PMID: 8808711

3

Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol.

Yu D, Liu B, Jing T, Sun D, Price JE, Singletary SE, Ibrahim N, Hortobagyi GN, Hung MC. Yu D, et al. Oncogene. 1998 Apr 23;16(16):2087-94. doi: 10.1038/sj.onc.1201729. Oncogene. 1998. PMID: 9572489

4

Role of erbB2 in breast cancer chemosensitivity.

Yu D, Hung MC. Yu D, et al. Bioessays. 2000 Jul;22(7):673-80. doi: 10.1002/1521-1878(200007)22:7<673::AID-BIES10>3.0.CO;2-A. Bioessays. 2000. PMID: 10878580 Review.

5

Overexpression of ErbB2 in cancer and ErbB2-targeting strategies.

Yu D, Hung MC. Yu D, et al. Oncogene. 2000 Dec 11;19(53):6115-21. doi: 10.1038/sj.onc.1203972. Oncogene. 2000. PMID: 11156524 Review.

6

Mechanisms of ErbB2-mediated paclitaxel resistance and trastuzumab-mediated paclitaxel sensitization in ErbB2-overexpressing breast cancers.

Yu D. Yu D. Semin Oncol. 2001 Oct;28(5 Suppl 16):12-7. doi: 10.1016/s0093-7754(01)90277-5. Semin Oncol. 2001. PMID: 11706391 Review.

7

Multiple signaling pathways involved in activation of matrix metalloproteinase-9 (MMP-9) by heregulin-beta1 in human breast cancer cells.

Yao J, Xiong S, Klos K, Nguyen N, Grijalva R, Li P, Yu D. Yao J, et al. Among authors: yu d. Oncogene. 2001 Dec 6;20(56):8066-74. doi: 10.1038/sj.onc.1204944. Oncogene. 2001. PMID: 11781819

8

Phosphorylation on tyrosine-15 of p34(Cdc2) by ErbB2 inhibits p34(Cdc2) activation and is involved in resistance to taxol-induced apoptosis.

Tan M, Jing T, Lan KH, Neal CL, Li P, Lee S, Fang D, Nagata Y, Liu J, Arlinghaus R, Hung MC, Yu D. Tan M, et al. Among authors: yu d. Mol Cell. 2002 May;9(5):993-1004. doi: 10.1016/s1097-2765(02)00510-5. Mol Cell. 2002. PMID: 12049736 Free article.

9

Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells.

Lee S, Yang W, Lan KH, Sellappan S, Klos K, Hortobagyi G, Hung MC, Yu D. Lee S, et al. Among authors: yu d. Cancer Res. 2002 Oct 15;62(20):5703-10. Cancer Res. 2002. PMID: 12384528

10

Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone.

Klos KS, Zhou X, Lee S, Zhang L, Yang W, Nagata Y, Yu D. Klos KS, et al. Among authors: yu d. Cancer. 2003 Oct 1;98(7):1377-85. doi: 10.1002/cncr.11656. Cancer. 2003. PMID: 14508823 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

13,933 results

Search Page

Filters